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(Accepted 8 October 1981) Sodium-potassium cotransport activity as genetic marker in essential hypertension J S DAVIDSON, L H OPIE, BRITTA KEDING Abstract Sodium-potassium cotransport activity is thought to be defective in essential hypertension and could be a useful genetic marker for susceptibility to essential hypertension. In this study cotransport activity in subjects with hypertension was compared with that in normotensive controls. The effects of ethnic differences, environment, and antihypertensive drugs were also studied. Mean cotransport activity was lower in hypertensive subjects than in controls of the same ethnic groups. There was, however, a large overlap between controls and hypertensive subjects. No ethnic or environmental influences were found.
The large overlap found suggests that sodium-potassium cotransport activity is not a useful genetic marker in essential hypertension.
Introduction
The sodium-potassium cotransport system in human erythrocytes was characterised by Wiley and Cooper in 1974 .1 This cotransport system is distinct from the sodium-potassium adenosine triphosphatase pump; is specifically inhibited by the diuretic frusemide; and transports sodium and potassium ions in the same direction, in a 1:1 ratio, either into or out of the cell depending on the prevailing concentration gradients of sodium and potassium.' Several reports have suggested that the sodiumpotassium cotransport system is defective in essential hypertension2-4 and that this is a useful genetic marker for susceptibility to essential hypertension, low cotransport activity being inherited as a single autosomal dominant gene. ' We compared cotransport activity in patients with essential hypertension and in normotensive controls, and assessed the effect of antihypertensive drug treatment on cotransport activity in different ethnic groups and in identical twins.
Subjects and methods
Sodium-potassium cotransport was assayed in sodium-loaded red cells by measuring frusemide-sensitive sodium and potassium efflux in the presence of ouabain, according to the method of Dagher and Garay.6 The only modification we made to this method was in the sodiumloading medium, which contained 50 mmol (mEq)/l sodium, 150 or (mEq)/l. In the case of hypertensive subjects receiving treatment, these criteria referred to the blood pressure before treatment, thus excluding patients with borderline hypertension. Table I shows the ages and blood pressures of the controls and hypertensive subjects. Hypertensive subjects were divided into two groups: those who had taken no drugs for at least two weeks before blood sampling (28) and those who were being treated with various combinations of the drugs listed in table II (44). In 17 subjects sodium-potassium cotransport activity was measured both on drug treatment and before the start of treat-BRITISH MEDICAL JOURNAL VOLUME 284 20 FEBRUARY 1982 ment or after treatment had been withdrawn for at least two weeks. Table II gives details of these patients and the drugs used. Subjects from the three ethnic groups were selected at random from hospital staff without prior knowledge of their blood pressure or family history.
Sodium-potassium cotransport activity was also measured in three pairs of twins, proved to be monozygotic by blood grouping and HLA typing (fig 1) .
Results
Assay reproducibility-In samples taken from 24 subjects and assayed in duplicate the mean variation was 13'", for potassium and 18"O for sodium frusemide-sensitive efflux.
Defiition of cotransport activity-In both controls and hypertensive subjects frusemide-sensitive effluxes of sodium and potassium were highly correlated, confirming that sodium and potassium ions are cotransported in a 1:1 ratio under these conditions. A plot of frusemide-sensitive sodium efflux against frusemide-sensitive potassium efflux for all controls and hypertensives had a slope of 0-95 when the best straight line was fitted by linear regression analysis, with a correlation coefficient of 0 81. Thus the mean of the frusemidesensitive effluxes of sodium and potassium is taken as the cotransport activity in each subject. When the data were analysed in terms of sodium and potassium fluxes separately the results were essentially the same.
Stability of cotransport activity over time-In seven subjects cotransport activity was measured repeatedly at intervals ranging from one to five months. The mean variation in each subject was 15) indicating that it is a stable value over time.
Comparison of controls and hypertensive subjects- Figure 2 shows the distribution of cotransport activity in the controls and hypertensive subjects. Mean cotransport activity was lower in treated and untreated hypertensive subjects than in controls of the same ethnic groups, but these differences were significant only when the ethnic groups were combined (table I) . A large overlap was apparent between controls and hypertensives. The passive permeabilities to sodium and potassium-that is, the rate constants for frusemide-resistant effluxwere similar to those previously reported" and were not significantly different in any of the groups studied (data not shown).
Ethnic comparison-In the subjects selected at random mean cotransport activity in blacks (19 subjects) was 0 309 A SEM 0-033, in subjects of mixed ancestry (14) 0-278-0 027, and in whites (16) 0 332 0 029. The differences were not significant.
Identical twins-In the three pairs of monozygotic twins there was a wide variation in cotransport activity between the pairs, while within each pair the values were closely concordant (fig 1) . 
Discussion
These results support the finding by Garay and Meyer that sodium-potassium cotransport activity tends to be reduced in essential hypertension.
A genetic marker for essential hypertension would be of great value (a) in distinguishing between essential and secondary hypertension, (b) in identifying "pre-hypertensive" subjects, and (c) as a research tool in identifying the environmental factors that cause hypertension in susceptible individuals. To be useful as such a marker any measurement must have at most a small overlap between proved normotensive and hypertensive groups. The large overlap found in this study suggests that sodium-potassium cotransport activity does not satisfy this condition and will not prove useful in hypertension, either as a marker in genetic studies or as a clinical test in individual patients. Moveover, the large overlap does not support the suggestion that low cotransport activity can identify the presence of a single autosomal dominant gene. 5 Black races are well known to be particularly susceptible to essential hypertension and South African blacks are no exception.8 9 These results suggest that this susceptibility is not due to an ethnic difference in sodium-potassium cotransport activity.
The similarity within pairs of monozygotic twins suggests that the variations in sodium-potassium contransport activity between individuals are due mainly to genetic factors and are not influenced appreciably by environmental factors. 
